Concepedia

Author

Francesco Perrone

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"ORCID

Also Known As

Annalisa Annunziata, C Gallo, F A Perrone, F Perrone, F. PERRONE, F. Perrone, FRANCESCO PERRONE, Francesca Annamaria Perrone, Francesco Perrone, Patrizia Popoli

373

Publications

11.5K

Citations

54

H-Index

82

Concepts

All Affiliations

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"University of Campania "Luigi Vanvitelli"Fondazione IRCCS Istituto Nazionale dei TumoriIstituti di Ricovero e Cura a Carattere ScientificoAzienda Ospedaliera S.Giuseppe Moscati
FP

About

Francesco Perrone is an author at Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" specializing in medicine, oncology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

30

58

3.7K

2

Health Sciences

17

21

1.5K

3

Public Health

3

3

48

4

Education

1

1

67

5

Nursing

1

1

23

Francesco Perrone

×

106

Publications

7K

Citations

41

H-Index

YearCitations

Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials

Massimo Di Maïo, Ciro Gallo, Natasha B. Leighl,

Journal of Clinical Oncology

2015

478

Pretreatment Quality of Life and Functional Status Assessment Significantly Predict Survival of Elderly Patients With Advanced Non—Small-Cell Lung Cancer Receiving Chemotherapy: A Prognostic Analysis of the Multicenter Italian Lung Cancer in the Elderly Study

Paolo Maione, Francesco Perrone, Ciro Gallo,

Journal of Clinical Oncology

2005

477

The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline

Massimo Di Maïo, Ethan Basch, Fabrice Denis,

Annals of Oncology

2022

435

c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases.

Chiara Carlomagno, Francesco Perrone, Ciro Gallo,

Journal of Clinical Oncology

1996

409

Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial

Sandro Pignata, Giovanni Scambia, Dionyssios Katsaros,

The Lancet Oncology

2014

386

Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine As First-Line Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 Study

Giuseppe Colucci, Roberto Labianca, Francesco Di Costanzo,

Journal of Clinical Oncology

2010

301

First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial

Cesare Gridelli, Fortunato Ciardiello, Ciro Gallo,

Journal of Clinical Oncology

2012

232

Carboplatin Plus Paclitaxel Versus Carboplatin Plus Pegylated Liposomal Doxorubicin As First-Line Treatment for Patients With Ovarian Cancer: The MITO-2 Randomized Phase III Trial

Sandro Pignata, Giovanni Scambia, Gabriella Ferrandina,

Journal of Clinical Oncology

2011

212

ESMO Guidance for Reporting Oncology real-World evidence (GROW)

Luís Castelo-Branco, Anna Pellat, Diogo Martins-Branco,

Annals of Oncology

2023

183

Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial

Sandro Pignata, Domenica Lorusso, Giovanni Scambia,

The Lancet Oncology

2015

170

Page 1